George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:1847–8.

Article  PubMed  Google Scholar 

Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125:616–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moscvin M, Ho M, Bianchi G. Overcoming drug resistance by targeting protein homeostasis in multiple myeloma. Cancer Drug Resist. 2021;4:1028–46.

PubMed  PubMed Central  Google Scholar 

Bianchi G, Anderson KC. Contribution of inhibition of protein catabolism in myeloma. Cancer J. 2019;25:11–8.

Article  CAS  PubMed  Google Scholar 

Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. lancet Oncol. 2016;17:27–38.

Article  CAS  PubMed  Google Scholar 

Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–52.

Article  PubMed  Google Scholar 

Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel DS, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396:186–97.

Article  CAS  PubMed  Google Scholar 

Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fotiou D, Roussou M, Gakiopoulou C, Psimenou E, Gavriatopoulou M, Migkou M, et al. Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. Blood Cancer J. 2020;10:109.

Article  PubMed  PubMed Central  Google Scholar 

Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4:e174519.

Article  PubMed  Google Scholar 

Portuguese AJ, Lipe B. Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion. Blood Adv. 2018;2:3443–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yui JC, Van Keer J, Weiss BM, Waxman AJ, Palmer MB, D’Agati VD, et al. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol. 2016;91:E348–52.

Article  CAS  PubMed  Google Scholar 

Chen Y, Ooi M, Lim SF, Lin A, Lee J, Nagarajan C, et al. Thrombotic microangiopathy during carfilzomib use: case series in Singapore. Blood Cancer J. 2016;6:e450.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gosain R, Gill A, Fuqua J, Volz LH, Knable MRK, Bycroft R, et al. Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment. Clin Case Rep. 2017;5:1926–30.

Article  PubMed  PubMed Central  Google Scholar 

Bhutani D, Assal A, Mapara MY, Prinzing S, Lentzsch S. Case report: carfilzomib-induced thrombotic microangiopathy with complement activation treated successfully with Eculizumab. Clin Lymphoma Myeloma Leuk. 2020;20:e155–e7.

Article  PubMed  Google Scholar 

Nguyen MN, Nayernama A, Jones SC, Kanapuru B, Gormley N, Waldron PE. Proteasome inhibitor-associated thrombotic microangiopathy: a review of cases reported to the FDA adverse event reporting system and published in the literature. Am J Hematol. 2020;95:E218–E22.

Article  PubMed  Google Scholar 

Ravindran A, Go RS, Fervenza FC, Sethi S. Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney Int. 2017;91:691–8.

Article  PubMed  Google Scholar 

Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115:379–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl J Med. 2013;368:2169–81.

Article  CAS  PubMed  Google Scholar 

Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 2006;70:423–31.

Article  CAS  PubMed  Google Scholar 

Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676–87.

Article  CAS  PubMed  Google Scholar 

Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122:2003–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ, et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol. 2016;27:1245–53.

Article  CAS  PubMed  Google Scholar 

Bu F, Zhang Y, Wang K, Borsa NG, Jones MB, Taylor AO, et al. Genetic analysis of 400 patients refines understanding and implicates a new gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2018;29:2809–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goicoechea de Jorge E, Lopez Lera A, Bayarri-Olmos R, Yebenes H, Lopez-Trascasa M. Rodriguez de Cordoba S. Common and rare genetic variants of complement components in human disease. Mol Immunol. 2018;102:42–57.

Article  CAS  PubMed  Google Scholar 

Rodriguez de Cordoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost. 2014;40:422–30.

Article  PubMed  Google Scholar 

Portuguese AJ, Gleber C, Passero FC Jr, Lipe B. A review of thrombotic microangiopathies in multiple myeloma. Leuk Res. 2019;85:106195.

Article  CAS  PubMed  Google Scholar 

Rosenthal A, Luthi J, Belohlavek M, Kortüm KM, Mookadam F, Mayo A, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016;6:e384.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stangl K, Stangl V. The ubiquitin-proteasome pathway and endothelial (dys)function. Cardiovasc. Res. 2010;85:281–90.

Article  CAS  PubMed  Google Scholar 

Kastritis E, Laina A, Georgiopoulos G, Gavriatopoulou M, Papanagnou ED, Papaiakovou E, et al. Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Leukemia. 2021;35:1418–27.

Article  CAS  PubMed  Google Scholar 

Blasco M, Martinez-Roca A, Rodriguez-Lobato LG, Garcia-Herrera A, Rosiñol L, Castro P, et al. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Br J Haematol. 2021;193:181–7.

Article  CAS  PubMed  Google Scholar 

Kitzler TM, Papillon J, Guillemette J, Wing SS, Cybulsky AV. Complement modulates the function of the ubiquitin-proteasome system and endoplasmic reticulum-associated degradation in glomerular epithelial cells. Biochim Biophys Acta. 2012;1823:1007–16.

Article  CAS  PubMed  Google Scholar 

Nozawa A, Ozeki M, Hori T, Kawamoto N, Hirayama M, Azuma E, et al. A heterozygous CFHR3-CFHR1 gene deletion in a pediatric patient with transplant-associated thrombotic microangiopathy who was treated with Eculizumab. J Pediatr Hematol Oncol. 2018;40:e544–e6.

Article  CAS  PubMed  Google Scholar 

Holliday EG, Smith AV, Cornes BK, Buitendijk G, Jensen RA, Sim X, et al. Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis. PLoS One. 2013;8:e53830.

Article  CAS  PubMed  PubMed Central  Google Scholar